	US 11,702,627 B2
	High cAMP yielding yeast strain and use thereof
Shaolan Zou, Tianjin (CN); Wenxuan Gao, Tianjin (CN); Yun Hu, Tianjin (CN); Shunhua Yang, Tianjin (CN); and Pingsheng Ma, Tianjin (CN)
Assigned to TIANJIN UNIVERSITY, Tianjin (CN)
Appl. No. 16/94,874
Filed by TIANJIN UNIVERSITY, Tianjin (CN)
PCT Filed Feb. 18, 2016, PCT No. PCT/CN2016/074067 § 371(c)(1), (2) Date Oct. 18, 2018, PCT Pub. No. WO2017/139959, PCT Pub. Date Aug. 24, 2017.
Prior Publication US 2019/0390157 A1, Dec. 26, 2019
Int. Cl. C12N 1/16 (2006.01); C12N 1/14 (2006.01); C12N 15/01 (2006.01); C12R 1/645 (2006.01)

CPC C12N 1/16 (2013.01) [C12N 15/01 (2013.01); C12N 1/145 (2021.05); C12N 2310/11 (2013.01); C12N 2310/141 (2013.01); C12N 2310/20 (2017.05); C12R 2001/645 (2021.05)]

11 Claims

1. A yeast for cyclic adenosine monophosphate (cAMP) synthesis, wherein the yeast includes:

a) first gene modifications to the protein kinase A (PKA) catalytic subunit encoding genes TPK1, TPK2 and TPK3, wherein the activity or expression of PKA is completely inhibited such that PKA-mediated feedback inhibition of cAMP synthesis is eliminated, wherein the first gene modifications inhibit the growth of the yeast;

b) a second gene modification to the Yak1 encoding gene thereby eliminating the growth inhibition caused by the first gene modifications such that the yeast grows normally and the cAMP yield by the yeast is increased relative to the cAMP yield by an unmodified yeast;

c) a third gene modification to the cAMP phosphodiesterase encoding gene PDE1 to reduce the degradation of cAMP, thereby increasing cAMP yield;

and wherein the yeast does not contain a functional ura3 gene.